Halozyme (HALO) Therapeutics announced that it intends to offer, subject to market conditions and other factors, $650M aggregate principal amount of convertible senior notes due 2031 and $650M aggregate principal amount of convertible senior notes due 2032.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Therapeutics’ Earnings Call Highlights Robust Growth
- Halozyme price target raised to $92 from $91 at Citizens JMP
- Halozyme Therapeutics Reports Strong Q3 2025 Results
- Halozyme’s Strong Q3 Performance and Promising Future Drive Buy Rating
- Halozyme Raises 2025 Guidance After Strong Q3 Results